Baxter International and Halozyme Therapeutics have announced the launch of Hyqvia in the US, a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI).
Developed by Halozyme, Baxter’s Hyqvia product includes immune globulin infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase.
University of Texas Southwestern Medical School paediatrics clinical professor Richard Wasserman said: "Hyqvia will have a significant impact on the treatment of primary immunodeficiency."
The US Food and Drug Administration (FDA) approved Hyqvia in September.
Hyqvia is indicated for adult PI patients, which allows a full monthly dose of IG to be administered with only one injection site and one infusion each month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Baxter BioScience president Ludwig Hantson said: "With our swift commercial introduction, we look forward to sharing Hyqvia with adult PI patients seeking an option with less frequent dosing than current subcutaneous treatments without compromising efficacy, safety and tolerability.
"The goal of Hyqvia is to allow people with PI to feel less like patients by reducing the treatment burden associated with weekly dosing and multiple injection sites per dose."
In 2013, Hyqvia received European approval to treat adult patients with primary immunodeficiency syndromes and myeloma, or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections.
The treatment is currently available in European nations such as Germany, Netherlands, Sweden, Norway, Denmark, Ireland and Italy.
Image: Baxter International Inc. headquarters. Photo: courtesy of Tactweb.
